{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T06:45:27Z","timestamp":1789541127638,"version":"build-2803163510"},"reference-count":30,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"4","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":["Clin Nucl Med"],"published-print":{"date-parts":[[2023,4]]},"abstract":"<jats:sec>\n            <jats:title>Purpose<\/jats:title>\n            <jats:p>We aimed to evaluate the impact of <jats:sup>18<\/jats:sup>F-fluciclovine PET\/CT imaging on failure-free survival (FFS) post\u2013salvage radiotherapy (SRT) for prostate cancer (PCa) recurrence.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Methods<\/jats:title>\n            <jats:p>Seventy-nine patients were recruited in a phase 2\/3 clinical trial to undergo <jats:sup>18<\/jats:sup>F-fluciclovine PET\/CT before SRT for PCa. Four patients with extrapelvic disease were excluded. All patients were followed up at regular intervals up to 48 months. Treatment failure was defined as a serum prostate-specific antigen level of \u22650.2 ng\/mL above the nadir after SRT, confirmed with an additional measurement, requiring systemic treatment or clinical progression. Failure-free survival was computed and compared between patients grouped according to <jats:sup>18<\/jats:sup>F-fluciclovine PET\/CT imaging findings.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>Results<\/jats:title>\n            <jats:p>Eighty percent (60\/75) of patients had a positive finding on <jats:sup>18<\/jats:sup>F-fluciclovine PET\/CT, of which 56.7% (34\/60) had prostate bed-only uptake, whereas 43.3% (26\/60) had pelvic nodal \u00b1 bed uptake. Following SRT, disease failure was detected in 36% (27\/75) of patients. There was a significant difference in FFS between patients who had a positive versus negative scan (62.3% vs 92.9% [<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001] at 36 months and 59.4% vs 92.9% [<jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001] at 48 months). Similarly, there was a significant difference in FFS between patients with uptake in pelvic nodes \u00b1 bed versus prostate bed only at 36 months (49.8% vs 70.7%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.003) and at 48 months (49.8% vs 65.6%; <jats:italic toggle=\"yes\">P<\/jats:italic> = 0.040). Failure-free survival was also significantly higher in patients with either negative PET\/CT or prostate bed-only disease versus those with pelvic nodal \u00b1 prostate bed disease at 36 (78% vs 49.8%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001) and 48 months (74.4% vs 49.8%, <jats:italic toggle=\"yes\">P<\/jats:italic> &lt; 0.001).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS<\/jats:title>\n            <jats:p>Findings on pre-SRT <jats:sup>18<\/jats:sup>F-fluciclovine PET\/CT imaging, even when acted upon to optimize the treatment decisions and treatment planning, are predictive of post-SRT FFS in men who experience PCa recurrence after radical prostatectomy. A negative <jats:sup>18<\/jats:sup>F-fluciclovine PET\/CT is most predictive of a lower risk of failure, whereas the presence of pelvic nodal recurrence portends a higher risk of SRT failure.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/rlu.0000000000004590","type":"journal-article","created":{"date-parts":[[2023,2,9]],"date-time":"2023-02-09T01:01:53Z","timestamp":1675904513000},"page":"e153-e159","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":11,"title":["Impact of 18F-Fluciclovine PET\/CT Findings on Failure-Free Survival in Biochemical Recurrence of Prostate Cancer Following Salvage Radiation Therapy"],"prefix":"10.1097","volume":"48","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4273-040X","authenticated-orcid":false,"given":"Ismaheel O.","family":"Lawal","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Marcus","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David M.","family":"Schuster","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Subir","family":"Goyal","sequence":"additional","affiliation":[{"name":"Biostatics Shared Resource"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omotayo A.","family":"Adediran","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vishal R.","family":"Dhere","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Winship Cancer Institute of Emory University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shreyas S.","family":"Joshi","sequence":"additional","affiliation":[{"name":"Department of Urology, Emory University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Olayinka A.","family":"Abiodun-Ojo","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Viraj A.","family":"Master","sequence":"additional","affiliation":[{"name":"Department of Urology, Emory University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pretesh R.","family":"Patel","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Winship Cancer Institute of Emory University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bridget","family":"Fielder","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Goodman","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph W.","family":"Shelton","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Winship Cancer Institute of Emory University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Omer","family":"Kucuk","sequence":"additional","affiliation":[{"name":"Department of Medical Oncology, Winship Cancer Institute of Emory University, Atlanta, GA."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bruce","family":"Hershatter","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Winship Cancer Institute of Emory University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raghuveer K.","family":"Halkar","sequence":"additional","affiliation":[{"name":"Department of Radiology and Imaging Sciences, Emory University, Atlanta, GA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ashesh B.","family":"Jani","sequence":"additional","affiliation":[{"name":"Department of Radiation Oncology, Winship Cancer Institute of Emory University"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2023,2,8]]},"reference":[{"key":"bib1-20250621","doi-asserted-by":"crossref","first-page":"4073","DOI":"10.1007\/s00261-020-02505-7","article-title":"Imaging assessment of local recurrence of prostate cancer after radical prostatectomy","volume":"45","year":"2020","journal-title":"Abdom Radiol (NY)"},{"key":"bib2-20250621","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1038\/s41585-021-00497-7","article-title":"Salvage therapy for prostate cancer after radical prostatectomy","volume":"18","year":"2021","journal-title":"Nat Rev Urol"},{"key":"bib3-20250621","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/S0090-4295(02)02411-1","article-title":"Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy","volume":"61","year":"2003","journal-title":"Urology"},{"key":"bib4-20250621","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1016\/j.euo.2018.09.010","article-title":"A systematic review on the role of imaging in early recurrent prostate cancer","volume":"2","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"bib5-20250621","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1016\/j.eururo.2016.01.029","article-title":"New clinical indications for (18)F\/(11)C-choline, new tracers for positron emission tomography and a promising hybrid device for prostate cancer staging: a systematic review of the literature","volume":"70","year":"2016","journal-title":"Eur Urol"},{"key":"bib6-20250621","doi-asserted-by":"crossref","first-page":"1601","DOI":"10.1007\/s00259-016-3329-1","article-title":"(18)F-FACBC (anti1-amino-3-(18)F-fluorocyclobutane-1-carboxylic acid) versus (11)C-choline PET\/CT in prostate cancer relapse: results of a prospective trial","volume":"43","year":"2016","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib7-20250621","doi-asserted-by":"crossref","first-page":"7374","DOI":"10.1007\/s00330-022-08802-7","article-title":"Comparing the diagnostic performance of radiotracers in prostate cancer biochemical recurrence: a systematic review and meta-analysis","volume":"32","year":"2022","journal-title":"Eur Radiol"},{"key":"bib8-20250621","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1001\/jamaoncol.2019.0096","article-title":"Assessment of 68Ga-PSMA-11 PET accuracy in localizing recurrent prostate cancer: a prospective single-arm clinical trial","volume":"5","year":"2019","journal-title":"JAMA Oncol"},{"key":"bib9-20250621","doi-asserted-by":"crossref","first-page":"362","DOI":"10.2967\/jnumed.118.212233","article-title":"Detection efficacy of 18F-PSMA-1007 PET\/CT in 251 patients with biochemical recurrence of prostate cancer after radical prostatectomy","volume":"60","year":"2019","journal-title":"J Nucl Med"},{"key":"bib10-20250621","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2967\/jnumed.119.226514","article-title":"Prospective evaluation of PSMA-targeted 18F-DCFPyL PET\/CT in men with biochemical failure after radical prostatectomy for prostate cancer","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib11-20250621","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.nucmedbio.2011.06.008","article-title":"Transport mechanisms of trans-1-amino-3-fluoro[1-(14)C]cyclobutanecarboxylic acid in prostate cancer cells","volume":"39","year":"2012","journal-title":"Nucl Med Biol"},{"key":"bib12-20250621","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1016\/j.nucmedbio.2015.07.005","article-title":"[(14)C]Fluciclovine (alias anti-[(14)C]FACBC) uptake and ASCT2 expression in castration-resistant prostate cancer cells","volume":"42","year":"2015","journal-title":"Nucl Med Biol"},{"key":"bib13-20250621","first-page":"406","article-title":"Clinical utility of 18F-fluciclovine PET\/CT in recurrent prostate cancer with very low (\u22640.3 ng\/mL) prostate-specific antigen levels","volume":"11","year":"2021","journal-title":"Am J Nucl Med Mol Imaging"},{"key":"bib14-20250621","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1007\/s11307-021-01644-7","article-title":"Positivity rate of [18F]fluciclovine PET\/CT in patients with suspected prostate cancer recurrence at PSA levels below 1 ng\/mL","volume":"24","year":"2022","journal-title":"Mol Imaging Biol"},{"key":"bib15-20250621","doi-asserted-by":"crossref","first-page":"4463","DOI":"10.1007\/s00259-021-05415-y","article-title":"A bicentric retrospective analysis of clinical utility of 18F-fluciclovine PET in biochemically recurrent prostate cancer following primary radiation therapy: is it helpful in patients with a PSA rise less than the Phoenix criteria?","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib16-20250621","doi-asserted-by":"crossref","first-page":"1986","DOI":"10.2967\/jnumed.114.143628","article-title":"Anti\u20131-amino-3-18F-fluorocyclobutane-1-carboxylic acid: physiologic uptake patterns, incidental findings, and variants that may simulate disease","volume":"55","year":"2014","journal-title":"J Nucl Med"},{"key":"bib17-20250621","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1016\/j.eururo.2019.01.049","article-title":"Gallium-68 prostate-specific membrane antigen positron emission tomography in advanced prostate cancer\u2014updated diagnostic utility, sensitivity, specificity, and distribution of prostate-specific membrane antigen-avid lesions: a systematic review and meta-analysis","volume":"77","year":"2020","journal-title":"Eur Urol"},{"key":"bib18-20250621","doi-asserted-by":"crossref","first-page":"2978","DOI":"10.1007\/s00259-021-05210-9","article-title":"Comparing the diagnostic performance of radiotracers in recurrent prostate cancer: a systematic review and network meta-analysis","volume":"48","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib19-20250621","doi-asserted-by":"crossref","first-page":"866","DOI":"10.2967\/jnumed.119.235028","article-title":"3-Year freedom from progression after 68Ga-PSMA PET\/CT-triaged management in men with biochemical recurrence after radical prostatectomy: results of a prospective multicenter trial","volume":"61","year":"2020","journal-title":"J Nucl Med"},{"key":"bib20-20250621","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1016\/S0140-6736(21)00581-X","article-title":"18F-fluciclovine-PET\/CT imaging versus conventional imaging alone to guide postprostatectomy salvage radiotherapy for prostate cancer (EMPIRE-1): a single centre, open-label, phase 2\/3 randomised controlled trial","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"bib21-20250621","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.2967\/jnumed.120.256784","article-title":"Salvage radiotherapy management decisions in postprostatectomy patients with recurrent prostate cancer based on 18F-fluciclovine PET\/CT guidance","volume":"62","year":"2021","journal-title":"J Nucl Med"},{"key":"bib22-20250621","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1016\/S0969-8043(03)00029-0","article-title":"Improved synthesis of anti-[18F]FACBC: improved preparation of labeling precursor and automated radiosynthesis","volume":"58","year":"2003","journal-title":"Appl Radiat Isot"},{"key":"bib23-20250621","doi-asserted-by":"crossref","first-page":"3648","DOI":"10.1200\/JCO.2016.67.9647","article-title":"Contemporary update of a multi-institutional predictive nomogram for salvage radiotherapy after radical prostatectomy","volume":"34","year":"2016","journal-title":"J Clin Oncol"},{"key":"bib25-20250621","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.3390\/cancers14112717","article-title":"PSMA PET-CT imaging predicts treatment progression in men with biochemically recurrent prostate cancer\u2014a prospective study of men with 3 year follow up","volume":"14","year":"2022","journal-title":"Cancers (Basel)"},{"key":"bib26-20250621","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1016\/j.eururo.2021.03.017","article-title":"Prostate-specific membrane antigen and fluciclovine transporter genes are associated with variable clinical features and molecular subtypes of primary prostate cancer","volume":"79","year":"2021","journal-title":"Eur Urol"},{"key":"bib27-20250621","doi-asserted-by":"crossref","first-page":"230","DOI":"10.2967\/jnumed.117.201749","article-title":"68Ga-PSMA-11 PET\/CT mapping of prostate cancer biochemical recurrence after radical prostatectomy in 270 patients with a PSA level of less than 1.0 ng\/mL: impact on salvage radiotherapy planning","volume":"59","year":"2018","journal-title":"J Nucl Med"},{"key":"bib28-20250621","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1007\/s00259-021-05557-z","article-title":"Outcome after PSMA-PET\/CT\u2013based salvage radiotherapy for nodal recurrence after radical prostatectomy","volume":"49","year":"2022","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"bib29-20250621","doi-asserted-by":"crossref","first-page":"715020","DOI":"10.3389\/fonc.2021.715020","article-title":"Feasibility and outcome of PSMA-PET\u2013based dose-escalated salvage radiotherapy versus conventional salvage radiotherapy for patients with recurrent prostate cancer","volume":"11","year":"2021","journal-title":"Front Oncol"},{"key":"bib30-20250621","doi-asserted-by":"crossref","first-page":"e201","DOI":"10.1016\/j.prro.2021.09.008","article-title":"Early outcomes and decision regret using PSMA\/MRI-guided focal boost for prostate cancer SBRT","volume":"12","year":"2022","journal-title":"Pract Radiat Oncol"},{"key":"bib31-20250621","article-title":"Nodal and osseous oligometastatic prostate cancer: a cohort including the introduction of PSMA-PET\/CT\u2013guided stereotactic and hypofractionated radiotherapy with elective nodal therapy","year":"2022","journal-title":"J Cancer Res Clin Oncol"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004590","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,21]],"date-time":"2025-06-21T20:05:32Z","timestamp":1750536332000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000004590"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,2,8]]},"references-count":30,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2023]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000004590","relation":{},"ISSN":["1536-0229","0363-9762"],"issn-type":[{"value":"1536-0229","type":"electronic"},{"value":"0363-9762","type":"print"}],"subject":[],"published":{"date-parts":[[2023,2,8]]}}}